No annual revenue total was found in IN8BIO, INC.'s SEC filings.
IN8BIO, Inc. (INAB) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $18.0 million in cash and investments and $2.2 million in total debt.
Revenue
—
Net income (TTM)
$-18.67M
+21.9% vs year-ago TTM
Operating cash flow (TTM)
$-14.36M
+16.5% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-1.49
+84.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
9.77M
+304.2% vs prior year
Net cash
$15.78M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INAB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1740279
- Former names
- Incysus Therapeutics, Inc. (until Sep 20, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M |
| Net income | -$19.4M | -$30.4M | -$30.0M | -$28.5M | -$14.7M |
| Diluted EPS | -$4.44 | -$17.05 | -$1.00 | -$1.36 | — |
| Operating cash flow | -$12.7M | -$24.1M | -$23.3M | -$24.1M | -$13.5M |
| Total assets | $32.3M | $20.9M | $33.7M | $33.0M | $42.2M |
| Total liabilities | $4.7M | $6.5M | $8.8M | $10.3M | $4.0M |
| Stockholders' equity | $27.6M | $14.5M | $24.9M | $22.7M | -$38.2M |
| Cash and investments | $27.1M | $11.1M | $21.3M | $18.2M | $37.0M |
| Total debt | $2.8M | $5.0M | $4.9M | $5.9M | $2.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Jun 1, 2026 | May 29, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change, Shareholder vote results
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Mar 26, 2026 | Dec 31, 2025 |
All 410 IN8BIO, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.